Frequencies of an Immunogenic HER-2/neu Epitope of CD8+ T Lymphocytes Predict Favorable Clinical Outcomes in Prostate Cancer

HER-2/neu is the human epidermal growth factor receptor 2, which is associated with the progression of prostate cancer (PCa). HER-2/neu-specific T cell immunity has been shown to predict immunologic and clinical responses in PCa patients treated with HER-2/neu peptide vaccines. However, its prognostic role in PCa patients receiving conventional treatment is unknown, and this was addressed in this study. The densities of CD8+ T cells specific for the HER-2/neu(780–788) peptide in the peripheral blood of PCa patients under standard treatments were correlated with TGF-β/IL-8 levels and clinical outcomes. We demonstrated that PCa patients with high frequencies of HER-2/neu(780–788)-specific CD8+ T lymphocytes had better progression-free survival (PFS) as compared with PCa patients with low frequencies. Increased frequencies of HER-2/neu(780–788)-specific CD8+ T lymphocytes were also associated with lower levels of TGF-β and IL-8. Our data provide the first evidence of the predictive role of HER-2/neu-specific T cell immunity in PCa.

[1]  M. Essand,et al.  Intratumoral administration of pro-inflammatory allogeneic dendritic cells improved the anti-tumor response of systemic anti-CTLA-4 treatment via unleashing a T cell-dependent response , 2022, Oncoimmunology.

[2]  A. Melcher,et al.  Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade , 2021, Frontiers in Immunology.

[3]  F. Korkes,et al.  The influence of testosterone suppression on HER2 immunoexpression in prostatic neoplastic tissue , 2021, Molecular and clinical oncology.

[4]  S. McArdle,et al.  Novel Combinatorial Approaches to Tackle the Immunosuppressive Microenvironment of Prostate Cancer , 2021, Cancers.

[5]  C. Bieberich,et al.  Castration-mediated IL-8 Promotes Myeloid Infiltration and Prostate Cancer Progression , 2019, bioRxiv.

[6]  A. Sica,et al.  Regulation of PD-L1 Expression by NF-κB in Cancer , 2020, Frontiers in Immunology.

[7]  Kristen Fousek,et al.  Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression. , 2020, Pharmacology & therapeutics.

[8]  Hongyu Zhao,et al.  Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors , 2020, Nature Medicine.

[9]  Eduard Batlle,et al.  Transforming Growth Factor-β Signaling in Immunity and Cancer. , 2019, Immunity.

[10]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[11]  U. Klein,et al.  NF-κB c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer , 2017, Cell.

[12]  S. Perez,et al.  Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide , 2016, Journal of Immunotherapy for Cancer.

[13]  S. Perez,et al.  MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4+ T-cells , 2016, Oncoimmunology.

[14]  N. Iqbal,et al.  Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications , 2014, Molecular biology international.

[15]  T. Sasada,et al.  Personalized peptide vaccine for treatment of advanced cancer. , 2014, Current medicinal chemistry.

[16]  L. Zitvogel,et al.  Trial Watch , 2004, Oncoimmunology.

[17]  L. Zitvogel,et al.  Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. , 2013, Immunity.

[18]  G. Galaktidou,et al.  Profiling serum HER-2/NEU in prostate cancer. , 2013, Hippokratia.

[19]  T. Sasada,et al.  Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine , 2013, Cancer Immunology, Immunotherapy.

[20]  M. Wroclawski,et al.  Her-2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis. , 2010, The Journal of urology.

[21]  A. Baldwin,et al.  Her2 Activates NF-κB and Induces Invasion Through the Canonical Pathway Involving IKKα , 2009, Oncogene.

[22]  Shiyong Li,et al.  NF-κB-Mediated HER2 Overexpression inRadiation-Adaptive Resistance , 2009, Radiation research.

[23]  B. Seliger,et al.  HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice , 2009, Cancer Immunology, Immunotherapy.

[24]  D. Horsfall,et al.  Elevated levels of HER‐2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential , 2008, The Prostate.

[25]  S. Matsueda,et al.  HER-2 peptides p776 and F7, N-terminal-linked with Ii-Key tetramer (LRMK) help the proliferation of E75-TCR+ cells: The dependency of help on the side chains of LRMK-extended peptide pointed towards the T cell receptor. , 2008, Oncology reports.

[26]  N. Kallinteris,et al.  Induction of potent CD4+ T cell‐mediated antitumor responses by a helper HER‐2/neu peptide linked to the Ii‐Key moiety of the invariant chain , 2007, International journal of cancer.

[27]  C. Roehrborn,et al.  Preoperative Plasma HER2 and Epidermal Growth Factor Receptor for Staging and Prognostication in Patients with Clinically Localized Prostate Cancer , 2007, Clinical Cancer Research.

[28]  S. Perez,et al.  Ii-Key/HER-2/neu(776-90) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors , 2007, Cancer Immunology, Immunotherapy.

[29]  E. Higashihara,et al.  Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy , 2006, International journal of urology : official journal of the Japanese Urological Association.

[30]  W. Hahn,et al.  Androgen-dependent regulation of Her-2/neu in prostate cancer cells. , 2006, Cancer research.

[31]  M. Nishimura,et al.  Interferon-γ renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells , 2006, Cancer Immunology, Immunotherapy.

[32]  Ingo K Mellinghoff,et al.  HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. , 2004, Cancer cell.

[33]  J. Gregg,et al.  Molecular alterations associated with LNCaP cell progression to androgen independence , 2004, The Prostate.

[34]  J. Lloreta,et al.  Her-2/neu Expression in Prostate Cancer , 2004, Clinical Cancer Research.

[35]  B. Seliger,et al.  HER-2/neu-Mediated Regulation of Components of the MHC Class I Antigen-Processing Pathway , 2004, Cancer Research.

[36]  B. Seliger,et al.  Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines , 2004, International journal of cancer.

[37]  J. Murray,et al.  Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer , 2004, Cancer Immunology, Immunotherapy.

[38]  Liang Cheng,et al.  Evaluation of HER‐2/neu expression in prostatic adenocarcinoma , 2002, Cancer.

[39]  M. Jordá,et al.  Her2 expression in prostatic cancer: a comparison with mammary carcinoma. , 2002, The Journal of urology.

[40]  G. Pawelec,et al.  Peptide HER2(776–788) represents a naturally processed broad MHC class II-restricted T cell epitope , 2001, British Journal of Cancer.

[41]  J. Manola,et al.  Her-2-neu expression and progression toward androgen independence in human prostate cancer. , 2000, Journal of the National Cancer Institute.

[42]  H. Ikeda,et al.  A HER2/NEU‐derived peptide, a Kd‐restricted murine tumor rejection antigen, induces HER2‐specific HLA‐A2402‐restricted CD8+ cytotoxic T lymphocytes , 2000, International journal of cancer.

[43]  K. Akiyoshi,et al.  Development of a cancer vaccine: peptides, proteins, and DNA , 2000, Cancer Chemotherapy and Pharmacology.

[44]  P. Musiani,et al.  Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER‐2/neu transgenic mice , 1998, International journal of cancer.